Sign Out
Healing of Erosive or Ulcerative Gastroesophageal Reflux Disease (GERD): PARIET is indicated for short-term (4 to 8 weeks) treatment in the healing and symptomatic relief of erosive or ulcerative gastroesophageal reflux disease (GERD). For those patients who have not healed after 8 weeks of treatment, an additional 8-week course of PARIET may be considered.
Maintenance of Healing of Erosive or Ulcerative Gastroesophageal Reflux Disease (GERD): PARIET is indicated for maintaining healing and reduction in relapse rates of heartburn symptoms in patients with erosive or ulcerative gastroesophageal reflux disease (GERD maintenance).
Healing of Duodenal Ulcers: PARIET is indicated for short-term (up to four weeks) treatment in the healing and symptomatic relief of duodenal ulcers. Most patients heal within four weeks.
Treatment of Pathological Hypersecretory Conditions, Including Zollinger-Ellison Syndrome: PARIET is indicated for the long-term treatment of pathological hypersecretory conditions, including Zollinger-Ellison Syndrome.
Symptomatic treatment of moderate to very severe Gastroesophageal reflux disease (symptomatic GERD): PARIET is indicated for the symptomatic treatment of moderate to very severe GERD.
Helicobacter pylori Eradication to Reduce the Risk of Duodenal Ulcer Recurrence in Adults: PARIET in combination with amoxicillin and clarithromycin as a three drug regimen, is indicated for the treatment of patients with H. pylori infection and duodenal ulcer disease (active or history within the past 5 years) to eradicate H. pylori. Eradication of H. pylori has been shown to reduce the risk of duodenal ulcer recurrence [see Pharmacology: Clinical Studies under Actions, and Dosage & Administration].
In patients who fail therapy, susceptibility testing should be done. If resistance to clarithromycin is demonstrated or susceptibility testing is not possible, alternative antimicrobial therapy should be instituted [see Pharmacology: Adjunctive effect on Helicobacter pylori Eradication under Actions].
